Your browser is no longer supported. Please, upgrade your browser.
GOSS Gossamer Bio, Inc. weekly Stock Chart
GOSS [NASD]
Gossamer Bio, Inc.
Index- P/E- EPS (ttm)-3.30 Insider Own1.40% Shs Outstand61.89M Perf Week1.62%
Market Cap1.03B Forward P/E- EPS next Y-3.37 Insider Trans0.18% Shs Float39.18M Perf Month4.11%
Income-201.80M PEG- EPS next Q-0.88 Inst Own63.60% Short Float14.53% Perf Quarter29.91%
Sales- P/S- EPS this Y-47.60% Inst Trans-1.94% Short Ratio8.47 Perf Half Y-14.55%
Book/sh4.95 P/B2.66 EPS next Y2.30% ROA-45.50% Target Price- Perf Year-40.21%
Cash/sh4.41 P/C2.99 EPS next 5Y31.90% ROE-53.80% 52W Range7.52 - 27.15 Perf YTD-15.80%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.53% Beta-
Dividend %- Quick Ratio12.50 Sales past 5Y- Gross Margin- 52W Low75.00% ATR0.75
Employees171 Current Ratio12.50 Sales Q/Q- Oper. Margin- RSI (14)54.39 Volatility4.73% 6.05%
OptionableYes Debt/Eq0.09 EPS Q/Q-76.50% Profit Margin- Rel Volume0.72 Prev Close12.82
ShortableYes LT Debt/Eq0.09 EarningsMay 12 AMC Payout- Avg Volume672.47K Price13.16
Recom1.70 SMA205.16% SMA501.24% SMA200-15.11% Volume485,564 Change2.65%
Jun-29-20Initiated H.C. Wainwright Buy $31
Apr-22-20Initiated Piper Sandler Overweight $30
Feb-27-20Initiated Barclays Overweight $21
Dec-03-19Resumed BofA/Merrill Buy
Oct-30-19Initiated Berenberg Buy $31
Mar-05-19Initiated SVB Leerink Outperform $30
Mar-05-19Initiated Evercore ISI Outperform $30
Mar-05-19Initiated BofA/Merrill Buy $30
Mar-05-19Initiated Barclays Overweight $27
Jul-03-20 06:27PM  
Jun-08-20 09:00AM  
Jun-02-20 04:25PM  
04:00PM  
03:19PM  
01:57PM  
12:54PM  
12:30PM  
11:40AM  
11:00AM  
10:01AM  
09:21AM  
06:20AM  
Jun-01-20 11:45PM  
06:10PM  
05:25PM  
12:00PM  
11:07AM  
10:00AM  
10:00AM  
07:35AM  
06:20AM  
May-31-20 10:50PM  
12:53PM  
08:30AM  
May-30-20 03:39PM  
03:30PM  
May-29-20 03:40PM  
02:40PM  
01:45PM  
12:50PM  
11:33AM  
10:32AM  
08:07AM  
May-28-20 09:20PM  
08:40PM  
02:55PM  
12:00PM  
11:30AM  
11:02AM  
10:30AM  
06:30AM  
May-27-20 11:25PM  
06:20PM  
04:30PM  
01:40PM  
01:00PM  
11:26AM  
10:22AM  
08:48AM  
07:36AM  
May-26-20 03:10PM  
02:35PM  
01:30PM  
12:52PM  
10:01AM  
09:00AM  
May-25-20 03:20PM  
02:30PM  
02:20PM  
06:20AM  
May-24-20 07:35PM  
02:35PM  
May-23-20 08:50AM  
May-22-20 05:45PM  
04:18PM  
03:55PM  
02:55PM  
May-21-20 06:06PM  
04:59PM  
04:25PM  
04:00PM  
06:20AM  
May-20-20 10:30PM  
07:09AM  
02:25AM  
May-19-20 06:53PM  
02:59PM  
01:50PM  
12:15PM  
12:12PM  
11:40AM  
06:20AM  
01:24AM  
May-18-20 09:45PM  
04:01PM  
02:40PM  
01:36PM  
10:15AM  
09:50AM  
09:12AM  
06:20AM  
May-17-20 01:08PM  
May-15-20 03:00PM  
02:30PM  
May-13-20 07:30PM  
01:55PM  
01:00PM  
10:20AM  
10:15AM  
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Giraudo BryanChief Financial OfficerJun 23Buy12.962,00025,9224,121Jun 23 05:01 PM
Dupont JakobChief Medical OfficerDec 30Option Exercise10.7140,000428,40040,000Dec 31 05:00 PM
Dupont JakobChief Medical OfficerDec 30Sale15.0040,000600,0040Dec 31 05:00 PM
Dupont JakobChief Medical OfficerDec 27Option Exercise10.711,99421,3561,994Dec 31 05:00 PM
Dupont JakobChief Medical OfficerDec 27Sale15.811,99431,5340Dec 31 05:00 PM